Skip to main content
Caplight Logo









The Vaccine Group

The Vaccine Group

Private
CambridgeHealthcare & Life Scienceshttps://thevaccinegroup.com/

Last Round

Grant

Oct 17, 2024

Est. Valuation

$12.35M

Total Funding Raised

$2.65M

Company Overview

The Vaccine Group is a biotechnology company that develops recombinant viral-vector vaccines and biotherapeutics for livestock and companion animals.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting, Government Contracts

AI Layer

Application

Keywords

veterinary vaccineviral vector platformanimal healthanimal pharmavaccine developmentbiotech R&Danimal biotechvaccine licensingveterinary medicineantigen designdrug discoverylivestock healthprotein designagritech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

The Vaccine Group Comparables

Compare The Vaccine Group with similar companies based on industry and business-model similarity.

The Vaccine Group comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
ViroVet
83%
Genvax Technologies
81%
AAVACC Pte. Ltd.
79%

The Vaccine Group Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantOct 17, 2024
GrantOct 14, 2024
GrantSep 5, 2024
SeedJan 20, 2020

Key People

Founding team and executive leadership

Jeremy Salt

Chief Executive Officer

Executive Team

The Vaccine Group Investors

Notable investors and investment history

The Vaccine Group investors
InvestorRounds
Frontier IP Group PlcSeed
Innovate UKGrant
Department for Environment, Food & Rural AffairsGrant

Market signals

Structured signals derived from secondary market and firmographic data.

  • Oct 29, 2024

    Monthly visitors grew 218% MoM, from 377 to 1.2K.

  • Oct 17, 2024

    $500K grant received from Innovate UK.

The Vaccine Group Filings

Explore SEC and related filing metadata, where available.

The Vaccine Group filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about The Vaccine Group's valuation, stock price, and market status.

Is The Vaccine Group a public or private company?

The Vaccine Group is a private company.

What is the current stock price of The Vaccine Group?

The Vaccine Group is a private company with no public stock price. No recent secondary market data is available.

How much is The Vaccine Group worth (valuation)?

The Vaccine Group's valuation is estimated at $12.3M based on funding round data.

Can I buy The Vaccine Group stock?

The Vaccine Group shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was The Vaccine Group's last funding round?

The Vaccine Group's most recent funding round was Grant on January 20, 2020.

Who are the main investors in The Vaccine Group?

Key investors in The Vaccine Group include Frontier IP Group Plc, Innovate UK, Department for Environment, Food & Rural Affairs.

Will The Vaccine Group IPO soon?

No public IPO plans have been announced for The Vaccine Group.

How can I track The Vaccine Group secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor The Vaccine Group's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersCambridge
Employee Range4
Year Founded2017
Last FundingOct 17, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?